Dear Jackie:
I will be at the Wilson World Hotel. Let's have lunch Friday and I will give you the latest status report. Let's make it about noon sharp, because I will have to run around 1:30 for my meeting at UT SW Medical School on the avant garde antirestenosis product proposal.
Why does it rain frogs when I leave town to do deals? This constant "croak" you hear for bhsl and lover HP_Type is boring to say the least. OK, so they can get back to "bud"..."wis"..."er" instead of David...David...David...
Unaudited year ending Dec 31, 1998
Stockholders Equity:
Common Stock, $0.001 Par Value; 100,000,000 shares Authorized; 4,128,424 Issued and Outstanding
Preferred Stock, $0.001 Par Value; 20,000,000 Authorized; -0- shares Issued and Outstanding
Paid in Capital: $928,381
Total Liabilities and Stockholders Equity: $820,538
The AUDITED form 10K will be available at the end of our fiscal year ending June 30th. THIS IS FROM MANAGEMENT'S REPORT AND FOR MANAGEMENT'S USE ONLY, AND IS FOR INFORMATION ONLY.
Once again, to answer to the unanswerable HP_Type's endless self-serving nit-picking; compassionate use for an indication is usually considered when no other effective therapy is available. What other therapies are available for CLI? (NONE) Orphan drug consideration by the FDA is usually considered when there are <150,000 annual patients. (Of course, they make the same consideration for the big Pharma Companies if the market is <$500 million.)
Last year there were about 100,000 amputations due to CLI. The market is about $150,000 in the U.S. Not one big company gives a damn about these patients (mostly old GI's who smoke, your diabetic Aunt Grace who's been on insulin for 50 years, and various other unglamorous old folks you would just as soon see die anyway). Let's see what other inane questions...oh yeah, where are all my microbiologists, pharmacologists, physiologists, statisticians, and other experts like HP THINKS he/she is, blah, blah, blah, yadda, yadda, yadda...?
Been there - done that HP. This product is ready. Besides, I've got protocols, dose ranging, GMP, cGPL contractors, CRC's, MONEY IN THE BANK. My burn rate? Give me a breeaakk! If I told you, you wouldn't believe it because you can't conceive of any other way to bring a product to market than the JNJ's, Shearing-Ploughs, Warner-Lamberts, Roche's, etc...with all their quack quack ducks that can only do ONE thing...Man, I luv ya, BUT WE'VE GOT SOME EAGLES!
And Trimedyne/Cardiodyne??? You must know Marvin Loeb, D.Sci....he's got dozens of mini-studies going, both in the U.S. and Europe. Once the best angiogenic (VEGF,bFGF, naked-though-encapsulated DNA or liposome delivered viral gene vectors) is demonstrated during the aforementioned studies in Germany - THIS SUMMER, then it's ball(s)-to-the-wall my friend, because TML recanalizing with anastomotic revascularization works!
Now what else ails you? Oh yes, the settlement...hmmm, go back and ask why the 10Q did not further explain the new litigation. Maybe its not "material". Or the other litigations that are becoming rather unmentionable and shameful.
Well, not only should this take you a while to digest, but I am sure that you will have to discuss this with your "spiritual guides".
Please do not hesitate to resume your constant "croaking". It always rains again. Sorry that I must again ask my shareholders to indulge you.
Now Jackie, if you would be so kind.....
David |
